Bone fracture repair by targeting of agents that promote bone healing

Patent metadata

Field	Value
Publication number	US-11623009-B2
Application number	US-202016927773-A
Country	US
Kind code	B2
Filing date	Jul 13, 2020
Priority date	May 29, 2015
Publication date	Apr 11, 2023
Grant date	Apr 11, 2023

Abstract

Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

First claim

We claim:

1. A method of treating a bone fracture, comprising the step of:
administering to a patient suffering from the bone fracture a therapeutic amount of a compound of the formula,
A-B-(MA) n -C-D,

wherein:
A is at least one negatively charged oligopeptide;
B is a spacer;
C is a linker having the formula:
-Gly-Gly-Pro-Xle

wherein:
Gly is a glycine;
Pro is a proline; and
Xle comprises at least one moiety selected from the group consisting of norleucine, leucine, isoleucine, a hydrophobic amino acid, and an amphipathic amino acid;
D is an active compound that promotes the healing of bone fractures selected from prostaglandin E1 or prostaglandin E2;
MA is a backbone structure which is linked to both B and C, wherein MA comprises at least one N-(2-Hydroxypropyl) methacrylamide; and
n is 1 to 1000.

2. The method of claim 1 , further comprising the step of: identifying a patient having a bone fracture.

3. The method of claim 1 , wherein A is an acidic oligopeptide.

4. The method of claim 3 , wherein the acidic oligopeptide comprises not less than and not more than 20 amino acids.

5. The method of claim 3 , wherein the acidic oligopeptide comprises one or more amino acids selected from the group consisting of D-aspartic acid, L-aspartic acid, D-glutamic acid, and L-glutamic acid.

6. The method of claim 1 , wherein B is a spacer comprising at least one glycine and at least one 8-amino-2,6-dioxaoctanoic acid.

7. The method of claim 1 , wherein C comprises at least one glycine.

8. The method of claim 1 , wherein D is prostaglandin E1.

9. The method of claim 1 , wherein the compound of the formula A-B-(MA) n -C-D is:

10. The method of claim 1 , wherein the compound of the formula: A-B-(MA) n -C-D, further comprises at least one molecule of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(3-methacrylamidopropyl)thiourei-do)benzoic acid, wherein the at least one molecule of 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(3-methacrylamidopropyl)thiourei-do)benzoic acid is linked to MA.

11. The method of claim 1 wherein the compound of the formula A-B-(MA) n -C-D further comprises a third group that linked to (MA) n.

12. The method of claim 11 , wherein the compound has the following formula:

13. The method of claim 1 , wherein the negatively charged oligopeptides comprise D-aspartic acid.

Assignees

• Purdue Research Foundation
• Univ Utah

Inventors

• Low Stewart Andrew
• Low Philip S
• Galliford Christopher
• Kopecek Jindrich
• Yang Jiyan

Classifications

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61K9/1075

  Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title

• A61L27/22 Primary

  Polypeptides or derivatives thereof {, e.g. degradation products} · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• A61L27/227

  Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24 · CPC title